Frontlight ResearchEarly access
CompletedNo phase
Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada
Key facts
- Who runs it
- PeriPharm
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 90 people enrolled
- Started
- 20 Jun 2024
- Ended
- 19 May 2026
- Type of study
- Observational
- Treatments tested
- Daridorexant 50 mg
- Record updated
- 27 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Signed ICF prior to any study-mandated procedure
- Has received a first prescription of daridorexant 50 mg to treat insomnia, treatment start has not exceeded 7 days prior to enrollment
- Ability to read and understand French or English
Who cannot take part
- Taking a concomitant medication to treat insomnia
- Already started daridorexant more than 7 days prior to enrollment.The 7-day period is necessary to allow flexibility between the time of prescription and PROxy first contact to participant. Beyond this 7-day period, patients may already have experienced benefits from daridorexant. To minimize bias in baseline results, these patients will be excluded
- History of daridorexant use in the past (i.e., samples provided by the physician before prescription)
- Patients participating in a clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this observational study is to evaluate the impact of daridorexant on quality of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia.
The group in the trial
- daridorexant
Patients who have been newly prescribed oral tablets of daridorexant 50 mg to treat their insomnia
Treatment: Daridorexant 50 mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 27 May 2026